Phio Pharmaceuticals Corp.
PHIO
$1.09
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 137.75% | 92.99% | 26.76% | 12.58% | -25.68% |
| Gross Profit | -137.75% | -92.99% | -26.76% | -12.58% | 25.68% |
| SG&A Expenses | 28.14% | 36.00% | 22.92% | 10.81% | 0.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 80.98% | 63.33% | 24.81% | 11.68% | -14.15% |
| Operating Income | -80.98% | -63.33% | -24.81% | -11.68% | 14.15% |
| Income Before Tax | -82.13% | -61.60% | -21.65% | -7.20% | 18.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.13% | -61.60% | -21.65% | -7.20% | 18.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.13% | -61.60% | -21.65% | -7.20% | 18.33% |
| EBIT | -80.98% | -63.33% | -24.81% | -11.68% | 14.15% |
| EBITDA | -80.96% | -63.32% | -24.81% | -11.83% | 13.89% |
| EPS Basic | 63.68% | 78.75% | 85.65% | 81.87% | 83.88% |
| Normalized Basic EPS | 63.68% | 78.75% | 85.65% | 81.41% | 83.62% |
| EPS Diluted | 63.68% | 78.75% | 85.65% | 81.87% | 83.88% |
| Normalized Diluted EPS | 63.68% | 78.75% | 85.65% | 81.41% | 83.62% |
| Average Basic Shares Outstanding | 238.95% | 349.83% | 660.56% | 570.28% | 591.21% |
| Average Diluted Shares Outstanding | 238.95% | 349.83% | 660.56% | 570.28% | 591.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |